Retatrutide

€350,00 EUR

In stock

Retatrutide, also known by the abbreviation RETA and the code LY3437943, is a new-generation synthetic peptide of the triple agonist class. A single molecule simultaneously activates three hormonal receptors: GLP-1, GIP, and glucagon. This is why it has become one of the most studied compounds in research on appetite regulation, energy metabolism, and glucose metabolism. At PurePeptides, Retatrutide is offered with a purity of over 99% and a certificate of analysis for each batch.

Each pen contains 30 mg of Retatrutide in 3 ml of solution (10 mg/ml) and allows for 300 clicks; each click corresponds to 0.1 mg (0.01 ml).

Storage: in the refrigerator, do not freeze, and protect from light.

Retatrutide is a 39-amino acid peptide developed by Eli Lilly. Previous agonists act on one or two receptors; Retatrutide combines activity on GLP-1, GIP, and glucagon into a single molecule.

GLP-1 and GIP are incretins: gut hormones released when eating that regulate insulin secretion and satiety. Glucagon, on the other hand, is a pancreatic hormone that acts primarily on the liver and increases energy expenditure. Adding this third receptor to the action of the incretins is what distinguishes Retatrutide from semaglutide (GLP-1 only) or tirzepatide (GLP-1 and GIP). It also explains the interest it has sparked in metabolic research.

Retatrutide's triple mechanism involves three receptors with complementary functions:

GLP-1 receptor: in the hypothalamus, it participates in the sensation of satiety; in the pancreas, it stimulates glucose-dependent insulin secretion and also slows gastric emptying.
GIP receptor: in the β-cells of the pancreas, it enhances insulin secretion, and in adipose tissue, it is involved in insulin sensitivity and lipid metabolism.
Glucagon receptor: in the liver, it stimulates fat oxidation and increases energy expenditure.

According to its development study (Coskun et al., 2022), Retatrutide is more potent than the natural hormones on the GIP receptor and less potent on the GLP-1 and glucagon receptors.

The development of Retatrutide was described in Cell Metabolism (Coskun et al., 2022), with preclinical studies and a first-in-human trial. Several phase 2 trials followed:

in adults with obesity (Jastreboff et al., New England Journal of Medicine, 2023), focusing on body weight;
in people with type 2 diabetes (Rosenstock et al., The Lancet, 2023), focusing on glycemic control and weight;
on liver fat in metabolic dysfunction-associated steatotic liver disease (Sanyal et al., Nature Medicine, 2024).

Eli Lilly is now developing the phase 3 program, with the TRIUMPH (obesity) and TRANSCEND (type 2 diabetes) trials. The first results were published in late 2025 and throughout 2026. Retatrutide is still in clinical development and is not yet authorized as a medication.

Retatrutide is a 39-amino acid peptide built upon the GIP sequence. It includes three non-natural amino acids. α-aminoisobutyric acid (Aib), at positions 2 and 20, protects it from degradation by the DPP-4 enzyme, and α-methyl-L-leucine occupies position 13. A 20-carbon fatty diacid is attached to the lysine at position 17, which allows it to bind reversibly to albumin and extends its half-life to approximately six days. Its CAS number is 2381089-83-2, its molecular formula is C221H342N46O68, and its molecular weight is 4731.33 g/mol.

It is supplied in a pen with a fixed concentration and volume: 30 mg in 3 ml of solution (10 mg/ml), with a scale of 300 clicks of 0.01 ml. As it is a solution, it does not require reconstituting a lyophilizate. The pen should be stored in a refrigerator, between 2 and 8 °C, without freezing and protected from direct light.

HPLC Analysis
(Purity >98%)

Express shipping with cold chain

24 months shelf life

Fast shipping throughout the EU

FAQ

RETA is the abbreviation commonly used for Retatrutide, a triple agonist of GLP-1, GIP, and glucagon receptors developed by Eli Lilly under the code LY3437943.

About three at once:

GLP-1: satiety and insulin secretion;
GIP: insulin secretion and lipid metabolism;
glucagon: fat oxidation in the liver and energy expenditure.

In terms of the number of receptors it acts upon:

semaglutide: GLP-1 only;
tirzepatide: GLP-1 and GIP;
retatrutide: GLP-1, GIP, and, in addition, the glucagon receptor.

The pen contains 30 mg in 3 ml and has 300 clicks. Each click corresponds to 0.1 mg of Retatrutide (0.01 ml of solution).

In a refrigerator, between 2 and 8 °C, do not freeze and protect from direct light. During shipping, it is kept in a cold chain.

Related Products

The product is intended exclusively for scientific research and laboratory use. It is not a medication or food product and is not intended for use in humans or animals for medical purposes.